Slide 1: Investor Presentation Spring 2026
INVESTOR PRESENTATION Spring 2026
Slide 2: Legal Disclaimer
LEGAL DISCLAIMER This presentation and associated commentary may contain forward-looking statements, including statements regarding expectations of future results of operations or financial performance of Doximity, market size and growth opportunities, the calculation of certain of our key financial
Slide 3: The Digital Platform for Doctors
THE DIGITAL PLATFORM FOR DOCTORS Leading Network Blue Chip Clients 85%+ 20/20 of all U.S. Top Hospitals and Health Systems Physicians1 Top Pharmaceutical Manufacturers3 >800K 109% Workflow Unique Net Revenue Active Providers2 Retention Rate4 1. As of 3/31/26. 2. For fiscal quarter ending 3/31/26. 3. T
Slide 4: Glaring Day-to-Day Inefficiencies
GLARING DAY-TO-DAY INEFFICIENCIES 70% of US HC communication still sent via fax1 75% of physicians attribute burnout to electronic health record (EHR) inefficiencies2 1. Konica Minolta, “New Facts About Fax in Healthcare,” 2023. 2. Tajirian et al., “The Influence of Electronic Health Record Use on Phy
Slide 5: Bringing Tech to Medicine
BRINGING TECH TO MEDICINE Inspired by enterprise tech Purpose-built for healthcare Networking Productivity Telehealth (Dialer Voice & Dialer Video), Digital Fax, Digital eSignature, Secure Messaging, On-Call Scheduling, AI Workflow Tools News & Scheduling eSignatures Newsfeed Medical Articles & News,
Slide 6: Purpose Built for Healthcare
PURPOSE BUILT FOR HEALTHCARE Professional Network Newsfeed Workflow Investor Presentation — May, 2026
Slide 7: Clinical AI Suite for Physicians
CLINICAL AI SUITE FOR PHYSICIANS A free, HIPAA- compliant suite of AI tools that is private to each clinician Scribe Ask Dialer Investor Presentation — May, 2026
Slide 8: Doximity Ask Doc Love
DOXIMITY ASK DOC LOVE “ Ask has been a game changer, I use it pretty much daily. It helps me get home at an earlier time, its HIPAA compliant, and helps me with education materials with my patients. —Kevin Parza, DO (Hematology) I asked Ask a question, then walked in to talk to the family augmented
Slide 9: Strong Engagement
STRONG ENGAGEMENT News 1, 2 Workflow 1 AI 1 >1M QAU >800K QAU ~½ of Workflow QAU 1. QAU are unique quarterly active prescribers (MD/DO/NP/PA/Pharmacist/Med Student/CRNA) Investor Presentation — May, 2026 2. As of 12/31/25
Slide 10: Engagement Throughout the Day
ENGAGEMENT THROUGHOUT THE DAY 1 1. Doximity usage by prescribers (MD/DO/NP/PA/CRNA/Pharmacist/Med Student) in fiscal quarter ending 9/30/25. For News, darker shades represent higher activity on Doximity's Newsfeed. For Workflow/AI, Investor Presentation — May, 2026 darker shades represent higher activ
Slide 11: Our Commercial Solutions
OUR COMMERCIAL SOLUTIONS Marketing Hiring Enterprise Workflow Educate on Latest News & Treatments Uncover Passive Candidates Reduce No-Shows & Leakage Relevance and personalization drive Rx’s & Referrals Find specialized talent #1 “Best in KLAS” Telehealth Video Conferencing Hundreds of thousands of
Slide 12: Marketing Solutions
MARKETING SOLUTIONS Largest Revenue Driver: Marketing Solutions Health Systems 2 17:1 ROI LexisNexis Pharma Leading Network Subscription Pricing Model 3 >73% of healthcare spend 1. Audience (e.g. specialty) ~10:1 ROI is decided by Doctors1 2. Number of audience members IQVIA Methodology 3. Type and
Slide 13: Land & Expand Sales Motion
LAND & EXPAND SALES MOTION 1 Land Initial Brands or Service Lines 2 Expand to Add’l Brands or Service Lines Service Service Brand Line Line 07 07 08 Service Service Service Brand Brand Brand Line Line Line 04 05 06 04 05 06 Service Service Service Service Brand Brand Brand Brand Line Line Line Line
Slide 14: Core Newsfeed Modules
CORE NEWSFEED MODULES We create customized packages for customers Long Form Video Short Form Investor Investor Presentation Presentation — — May, May, 2026 2026
Slide 15: Point of Care Modules
POINT OF CARE MODULES Point of Care Formulary Investor Investor Presentation Presentation — — May, May, 2026 2026
Slide 16: Dynamic Integrated Offering
DYNAMIC INTEGRATED OFFERING Increased unique reach Higher quality engagements 300+ Data & Insights Inputs HCP behavior change, AI Orchestration increased NRx lift and impact Proprietary Doximity, IQVIA, Engine Brand & Content Signals Investor Presentation — May, 2026
Slide 17: AI Search Offering
AI SEARCH OFFERING Acceleration of ecosystem message Ask AI Placement Investor Presentation — May, 2026
Slide 18: Large & Growing Total Addressable Market
LARGE & GROWING TOTAL ADDRESSABLE MARKET $18.5B $4.3B + $6.9B + $7.3B Pharmaceutical Marketing1 Health System Marketing and Staffing2 Telehealth3 Total 1. Pharmaceutical Marketing TAM represents total annual marketing spend by Pharmaceutical Manufacturers to Doctors. Source: IQVIA 2019 US ChannelDyna
Slide 19: Pharma Brand Opportunity
PHARMA BRAND OPPORTUNITY Our Penetration into Our Penetration into Estimated Share of HCP Marketing >$100M US Mega Brands1 <$100M US Mid-Tier Brands2 Budget (all >$1m Brands)3 3% 1. As of March 31, 2026. # of brands with $100m+ in US sales (based on data from Evaluate Pharma) where Doximity has reve
Slide 20: Q4 Key Revenue Metrics
Q4 KEY REVENUE METRICS LAND & EXPAND Number of Customers w/ $500K+ of Revenue1 Net Revenue Retention2 109% Total Company 125 $500K+ + 6% y/y Top-20 Customers 114% 1. Refer to appendix for the definition of customers with trailing 12-month subscription revenue greater than $500,000. 2. Refer to append
Slide 21: Attractive Revenue Growth & Margin Profile
ATTRACTIVE REVENUE GROWTH & MARGIN PROFILE Revenue1 Adj. EBITDA & Margin1,2 55% 22% 31% 49% CAGR CAGR 55% 48% 44% 44% 31% 3 3 1. Fiscal Year ended March 31. 2. Refer to appendix for the definition and non-GAAP reconciliation of Adjusted EBITDA and Adjusted EBITDA margin. Investor Presentation — May,
Slide 22: Founder-Led, Mission Driven
FOUNDER-LED, MISSION DRIVEN 880 Jeff Tangney CEO & Co-Founder Steve Zatz President Matt Sonefeldt CFO EMPLOYEES1 >40% Lisa Greenbaum Jey Balachandran Amit Phull, MD CCO CTO Chief Clinical Experience Officer IN R&D1 Ben Greenberg Joel Davis John Vaughn SVP Commercial Products SVP Product General Couns
Slide 23: Company Highlights
COMPANY HIGHLIGHTS 1 Leading digital platform for doctors 2 Powerful network effects 3 Sustainable revenue growth & profitability 4 Veteran vertical team 5 Massive near-term market opportunity fueled by shift to digital & AI Investor Presentation — May, 2026
Slide 24: Appendix: Non-GAAP Financial Measures
APPENDIX: NON-GAAP FINANCIAL MEASURES To supplement our consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP measures of financial performance: Non-GAAP g
Slide 25: Appendix: Adjusted EBITDA & Margin Non-GAAP Reconciliation
APPENDIX: ADJUSTED EBITDA & MARGIN NON-GAAP RECONCILIATION Year Ended March 31, 2021 2022 2023 2024 2025 2026 (in thousands) Net Income $50,210 $154,783 $112,818 $147,582 $223,185 $196,051 Adjustments: Acquisition and other related expenses 496 254 30 ‒ ‒ 1,616 Stock-based compensation 7,252 31,442